European Union: The EU General Court's Ruling On Pay For Delay

The EU General Court ("Court") reduced the fines imposed on Servier SAS and its subsidiaries ("Servier") from a total of €428 million to €315 million (see press release no. 194/18), thereby partially annulling a European Commission ("Commission") decision.

The Court confirmed the Commission's finding that most of Servier's practices (patent settlement agreements including connected side deals) violated the European cartel ban ( Article 101 TFEU) since they hindered the market entry of cheaper generic drugs. The Court, however, rejected the Commission's decision on the abuse of market power by Servier (Article 102 TFEU) since the Commission did not correctly define the relevant market.

Background

The pharmaceutical sector has been the focus of the Commission's antitrust investigations for more than 10 years due to high prices, low innovation, and generic manufacturers' relatively hesitant market entries after drug patents' expirations. The Commission's investigations focus on patent filings, patent enforcement, and dispute settlement agreements concerning pharmaceutical products' introduction to the market. The latter include settlement agreements between originator companies and generic companies aimed at delaying the marketing of generic drugs – so-called "pay-for-delay" or "reverse patent settlement" agreements – which can constitute restrictions of competition by object or by effect under the European cartel ban (Article 101 TFEU).

In its Lundbeck decision of 2016 ( T-472/13, appeal still pending at the European Court of Justice), the Court decided for the first time on a pay-for-delay constellation. However, the decision left market observers with several questions regarding the delimitation between allowed settlement agreements in pharmaceutical patent lawsuits on the one hand, and settlement agreements that constitute anticompetitive pay-for-delay agreements, on the other.

The Court, in Servier, has now shed some light on this issue.

The Facts

In 2001, Servier filed a patent relating to erbumine, a drug intended for the treatment of hypertension and heart failure, and its manufacturing process. The patent was granted in 2004. When the patent's validity was challenged, Servier entered into settlement agreements, including several highly complex side deals (such as licensing, distribution and acquisition agreements) with five generic companies. The agreements required those five companies to refrain from entering the market or challenging patent's validity. The Commission, in its 2014 decision, concluded that all of these agreements constituted restrictions of competition by object and by effect and that Servier's overall settlement strategy would be exclusionary and therefore constitute abuse of a dominant position. On that basis, the Commission imposed fines in the amount of €330.99 million on Servier and a total of €131.53 million on the five generic companies that had been parties to the various settlement agreements.

Decision of the Court In the case of Servier, the Court confirmed that all but one of the settlement agreements (including the connected side deals) that Servier entered into constituted restrictions of competition by object and thus violated the European cartel ban (Article 101 TFEU). The Court, however, refuted the Commission's finding of the abuse of a dominant position (Article 102 TFEU).

Cartel Ban (Article 101 TFEU)

According to the Court, Servier and the generic companies were potential competitors, as the generic companies would have had a more concrete possibility of market entry with their generic drug perindropil. The Court acknowledged that a patent, when granted by a public authority, is presumed to be valid and that a patentee's ownership of that right must be presumed lawful. The Court also highlighted, however, that the existence of a patent would not necessarily prevent the Court from finding that potential competition exists, particularly if it is possible for the generic companies to contest the patent's validity.

The Court also emphasized the importance of settlement agreements in general, and acknowledged that settlements in patent lawsuits are not necessarily contrary to competition law. When the originator company (i.e., the patentee) grants advantages to the generic company, inducing it to refrain from entering the market or challenging the originator company's patent, the inducement – not the parties' recognition of the settlement over the patent's validity – must be regarded as the real reason for the restriction of competition introduced by the agreement.

The Court therefore confirmed that, in light of the diverse and complex nature of the arrangements for granting an inductive benefit for the generic companies to refrain from entering the market or challenging Servier's patent, most of the settlement agreements (including the connected side deals) between Servier and the generic companies infringed Article 101 TFEU.

Regarding the agreement between Servier and one of the generic companies, Krka, the Court rejected the Commission's finding of a violation of Article 101 TFEU due to the specific facts of the case. In particular, the Court did not agree with the Commission's assessment that Krka's agreement with Servier induced Krka to withdrawal from the market, and that – without the agreement – Krka would probably have entered the market. Thus the Court annulled the fine that pertained to the settlement agreement between Servier and Krka.

Abuse of Dominance (Article 102 TFEU)

Finally, the Court completely annulled the fines imposed on Servier on the basis of Article 102 TFEU, taking the view that the Commission erred in defining the relevant market by wrongly assuming that perindopril differed, in terms of therapeutic use, from alternative drugs. The Court found that the Commission's analysis underestimated the patient's propensity and readiness for alternatives, thus attributing excessive importance to the price factor.

Outlook

In Servier, the Court seems to review the Commission's market definitions more closely than it has in previous cases, as illustrated by the Servier Court's discussion of the Article 102 TFEU violation. Given the trend among authorities to attempt to extend Article 102 TFEU to, inter alia, cover excessive pricing in the pharmaceutical sector, the Court's change in direction, should it last, could turn out to be of further significance.

In any event, Servier should serve as encouragement to originator and generic companies to carefully consider whether potential advantages promised in settlement agreements might constitute potential market restrictions in violation of Article 101 TFEU.

Comment: This article is based on the Court's official press release no. 194/18. The full text of the Court's decision is currently only available in French. We will examine the English version in detail after its publication and keep you updated on any relevant additional information contained therein.

Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Morrison & Foerster LLP. All rights reserved

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Wolfgang Schönig
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
 
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Sign Up
Gain free access to lawyers expertise from more than 250 countries.
 
Email Address
Company Name
Password
Confirm Password
Position
Industry
Mondaq Newsalert
Select Topics
Select Regions
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions